Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NKT3964 |
| Synonyms | |
| Therapy Description |
NKT3964 is a proteolysis-targeted chimera (PROTAC) that targets CDK2 for degradation, potentially resulting in decreased tumor cell proliferation and antitumor activity (Eur J Cancer 211 (2024): 114453). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NKT3964 | NKT 3964|NKT-3964 | CDK2 Inhibitor 31 | NKT3964 is a proteolysis-targeted chimera (PROTAC) that targets CDK2 for degradation, potentially resulting in decreased tumor cell proliferation and antitumor activity (Eur J Cancer 211 (2024): 114453). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |